Three AI Deals in 72 Hours
Novo Nordisk announced on September 16, 2026, that it is partnering with Anthropic to weave the AI company’s Claude models and its specialized Claude Science research platform into its drug-discovery workflows. The announcement came within 72 hours of two other Novo Nordisk AI deals, a macrocycle drug discovery partnership with Orbis Medicines disclosed September 17 targeting cardiometabolic disease, and continued work under a joint AI Innovation Center Novo established earlier in 2026 with Amazon Web Services. Novo Nordisk President and CEO Mike Doustdar said the collaboration with Anthropic will significantly strengthen the company’s R&D organization, part of a stated ambition to become what he called the world’s most AI-driven healthcare company.
What Claude Science Actually Does
Claude Science, which Anthropic launched in beta earlier in 2026, functions as a unified research workbench that brings together more than 60 scientific databases and tools spanning genomics, single-cell analysis, proteomics, structural biology and cheminformatics, areas that researchers previously had to navigate through separate, disconnected software. Inside the platform, scientists can design CRISPR screening experiments, analyze single-cell RNA sequencing data, and generate three-dimensional protein structures or chemistry drawings without switching between specialized tools built by different vendors. Anthropic co-founder and CEO Dario Amodei said providing safe, high-performance and reliable frontier models to top-tier researchers can shorten research timelines, framing the tool as infrastructure for scientists rather than a general-purpose chatbot.
A Concrete Use Case Already in Production
Novo Nordisk is not treating the partnership as purely experimental. The company said it already uses Claude to automate clinical-trial report generation, cutting patient-documentation timelines from months to minutes, a specific, currently deployed application rather than a future promise. The company and Anthropic said they will jointly address additional drug-discovery challenges identified by Novo’s scientists and computational teams, developing targeted solutions for specific scientific workflows meant to support biological reasoning during early-stage research.
Why Novo Nordisk Is Moving So Fast
The urgency behind Novo’s AI buildout traces directly to its business situation. Ozempic and Wegovy, the GLP-1 drugs that turned Novo into one of Europe’s most valuable companies, face generic competition beginning in the early 2030s, and the company is locked in an intense competitive race with Eli Lilly in the obesity drug market. Novo’s second-quarter 2026 results showed adjusted sales of 78.5 billion Danish kroner, up 7 percent, against pipeline impairments of 6.3 billion kroner, including 4 billion kroner tied to the discontinued candidate monlunabant, a reminder that the company badly needs its next generation of drugs to work and to arrive faster than the last one did. Anthropic is Novo’s third major AI platform partnership in under six months, following an earlier collaboration with OpenAI applied across drug discovery and commercial operations.
Skepticism About Whether AI Speeds Up the Slow Part
Industry analysts note that AI research workbenches like Claude Science accelerate the parts of drug discovery that involve reading literature, designing experiments and analyzing data, but do not shorten the parts that actually take the longest: synthesizing candidate compounds, running animal studies, and conducting multi-year human clinical trials. Novo’s own pipeline troubles illustrate the limit; monlunabant failed despite the company’s existing computational tools, underscoring that better software for hypothesis generation does not guarantee a molecule will survive contact with human biology. Some pharmaceutical-industry observers also point out that signing high-profile AI partnerships has become as much a signal to investors and Wall Street as a genuine operational bet, since financial terms in the Anthropic and Orbis deals were not disclosed, making it hard for outsiders to judge how much computing and personnel resources Novo is actually committing.
What to Watch Next
The real test of the Anthropic partnership will be whether Novo’s R&D organization can point to specific molecules or targets that moved from computational hypothesis to laboratory validation faster than under its old workflow, the kind of concrete before-and-after comparison that has been rare across the industry’s AI partnerships so far. Novo has not set a public timeline for when the first Claude Science-assisted discovery might reach clinical testing, and Anthropic’s platform remains in beta for outside biomedical researchers more broadly. With three AI deals announced in a single week and a patent cliff looming at the start of the next decade, Novo Nordisk has committed itself publicly to a strategy that will only be judged a success if it produces approved medicines, not just faster paperwork and tidier databases.
Photo: https://kaboompics.com/ / PEXELS via Pexels
